These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7290262)

  • 1. Hormonal therapy and alterations of immunity in prostatic cancer.
    Ablin RJ
    Neoplasma; 1981; 28(3):345-50. PubMed ID: 7290262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of estrogen on tumor-associated immunity in patients with adenocarcinoma of the prostate.
    Ablin RJ; Bhatti RA; Guinan PD
    Cancer Res; 1978 Nov; 38(11 Pt 1):3702-6. PubMed ID: 698929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulatory effects of estrogen on immunologic responsiveness. III. Effect of hormonal versus nonhormonal therapy on tumor-associated immunity in prostatic cancer.
    Ablin RJ
    Am J Reprod Immunol (1980); 1981 Aug; 1(4):206-9. PubMed ID: 7337156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further evaluation of the effect of estrogen on tumor-associated immunity in prostatic cancer.
    Ablin RJ; Bhatti RA; Guinan PD
    Isr J Med Sci; 1979 Jan; 15(1):9-11. PubMed ID: 422345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-associated immunity in prostatic cancer as evaluated by tube antigen-induced leukocyte adherence inhibition: reactivity and specificity of responsiveness, and relationship to stage, grade and therapy.
    Bhatti RA; Ablin RJ; Guinan PD
    J Reticuloendothel Soc; 1979 Apr; 25(4):389-95. PubMed ID: 458777
    [No Abstract]   [Full Text] [Related]  

  • 6. Modulatory effects of oestrogen on immunological responsiveness. II. Suppression of tumour-associated immunity in patients with prostatic cancer.
    Ablin RJ; Bhatti RA; Guinan PD; Khin W
    Clin Exp Immunol; 1979 Oct; 38(1):83-91. PubMed ID: 93529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-mediated immunity in prostatic cancer.
    Ablin RJ; Bhatti RA; Nagubadi S; Zamora S; Guinan PD
    Clin Oncol; 1980 Sep; 6(3):253-64. PubMed ID: 7428203
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunomodulatory effects of oestrogen in prostatic cancer: update and further consideration.
    Ablin RJ
    Allergol Immunopathol (Madr); 1981; 9(1):63-70. PubMed ID: 7258047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulatory effects of oestrogen on immunologic responsiveness. I. Inhibition of DNA synthesis in peripheral blood lymphocytes from patients with Peyronie's disease, prostatic cancer and transsexuals and a commentary.
    Ablin RJ; Bruns GR; Guinan PD; Al Sheik H; Bush IM
    Eur Urol; 1979; 5(6):359-68. PubMed ID: 467472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible suppression of host resistance by estrogen therapy for prostatic cancer.
    Ablin RJ
    Can Med Assoc J; 1976 Dec; 115(11):1082-4. PubMed ID: 1000436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnostics and therapy of the carcinoma of the prostate (author's transl)].
    Schnorr D; Guddat HM; Neuser D; Correns HJ; Dörner G; Mau S
    Zentralbl Chir; 1979; 104(7):436-45. PubMed ID: 112805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.
    Dzojic H; Loskog A; Tötterman TH; Essand M
    Prostate; 2006 Jun; 66(8):831-8. PubMed ID: 16491482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen in refractory metastatic carcinoma of the prostate.
    Glick JH; Wein A; Padavic K; Negendank W; Harris D; Brodovsky H
    Cancer Treat Rep; 1980; 64(6-7):813-8. PubMed ID: 7427966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Regression and disappearance of bone metastasis in a case of prostatic carcinoma after bilateral orchidectomy and oestrogen therapy (author's transl)].
    Suhler A
    J Urol (Paris); 1981; 87(4):227-9. PubMed ID: 7264352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic responsiveness & tumour growth of the Dunning R3327 rat prostatic adenocarcinoma following cryosurgery & orchiectomy.
    Eskandari H; Ablin RJ; Bhatti RA
    Indian J Exp Biol; 1982 Dec; 20(12):872-4. PubMed ID: 7183523
    [No Abstract]   [Full Text] [Related]  

  • 16. The immune response to prostate cancer: an evaluation and a review.
    Guinan P; Bhatti R; Sharifi R; Sundar B; Nagubadi S; Baumgartner G
    J Surg Oncol; 1980; 15(4):309-18. PubMed ID: 7005544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of chemohormonal therapy as an initial treatment for stage D2 prostatic cancer--effect of UFT administration combined with hormonal therapy].
    Honda M; Takasaki E; Suzuki T; Maeda S; Imai T; Hosoya Y; Chen JA
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):105-9. PubMed ID: 7826063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormones and radiation therapy in locally advanced adenocarcinoma of the prostate.
    Lawton CA
    Semin Radiat Oncol; 2003 Apr; 13(2):141-51. PubMed ID: 12728443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
    Berenguer Sánchez A
    Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of advanced prostatic cancer].
    Hedlund PO
    Lakartidningen; 2000 Aug; 97(32-33):3466-9. PubMed ID: 11037588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.